**Title:** **Histopathological correlates of hemorrhagic lesions on ex vivo MRI in immunized Alzheimer’s disease cases**

**Running title: Histopathology of ARIA-H**

Ashley A. Scherlek­­1, Mariel G. Kozberg1,2, James A.R. Nicoll­­3, Valentina Perosa2, Whitney M. Freeze4, Louise van der Weerd4,5, Brian J. Bacskai1, Steven M. Greenberg2, Matthew P. Frosch6, Delphine Boche3, Susanne J. van Veluw1,2,4\*

*1 MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA*

*2 J. Philip Kistler Stroke Research Center, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA*

*3 Clinical Neurosciences, Clinical and Experimental Sciences School, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK*

*4 Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands*

*5 Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands*

*6 Neuropathology Service, C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA*

\* Corresponding author: Susanne J. van Veluw, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, 114 16th street, Charlestown, 02129 MA, USA, svanveluw@mgh.harvard.edu

**Abstract**

Hemorrhagic Amyloid-Related Imaging Abnormalities (ARIA-H) on MRI are frequently observed adverse events in the context of amyloid β (Aβ) immunotherapy trials in patients with Alzheimer’s disease (AD). The underlying histopathology and pathophysiological mechanisms of ARIA-H remain largely unknown, although coexisting cerebral amyloid angiopathy (CAA) may play a key role. Here, we used ex vivo MRI in cases that underwent Aβ immunotherapy during life to screen for hemorrhagic lesions and assess underlying tissue and vascular alterations. We hypothesized that these lesions would be associated with severe CAA.

Ten cases were selected from the long-term follow-up study of patients who enrolled in the first clinical trial of active Aβ immunization with AN1792 for AD (iAD cases). Eleven matched non-immunized AD cases from an independent brain brank were used as ‘controls’ (cAD cases). Formalin-fixed occipital brain slices were imaged at 7T MRI to screen for hemorrhagic lesions (i.e. microbleeds and cortical superficial siderosis). Samples with and without hemorrhagic lesions were cut and stained. AI-assisted quantification of Aβ plaque area, cortical and leptomeningeal CAA area, density of iron and calcium positive cells, and reactive astrocytes and activated microglia was performed.

On ex vivo MRI, cortical superficial siderosis was observed in 5/10 iAD cases compared to 1/11 cAD cases (κ = 0.5). On histopathology, these areas revealed iron and calcium positive deposits in the cortex. Within the iAD group, areas with siderosis on MRI revealed greater leptomeningeal CAA and concentric splitting of the vessel walls compared to areas without siderosis. Moreover, greater density of iron positive cells in the cortex was associated with lower Aβ plaque area and a trend towards increased post-vaccination antibody titers.

This work highlights the use of ex vivo MRI to investigate the neuropathological correlates of hemorrhagic lesions observed in the context of Aβ immunotherapy. These findings suggest a possible role for CAA in the formation of ARIA-H, awaiting confirmation in future studies that include brain tissue of patients who received passive immunotherapy against Aβ with available in vivo MRI during life.

*Keywords:* amyloid β, immunotherapy, cerebral amyloid angiopathy, siderosis

*Abbreviations:*

Aβ: amyloid β

AD: Alzheimer’s disease

AI: artificial intelligence

APOE: apolipoprotein

ARIA: amyloid-related imaging abnormalities

CAA: cerebral amyloid angiopathy

CD68: cluster of differentiation 68

DAB: 3,3'-Diaminobenzidine

FLAIR: fluid-attenuated inversion recovery

GFAP: glial fibrillary acidic protein

GRE: gradient echo

H&E: hematoxylin & eosin

PiB: Pittsburgh compound B

TSE: turbo spin echo

**Introduction**

A prominent feature of Alzheimer’s disease (AD) is the accumulation of the amyloid β (Aβ) peptide in the brain in the form of plaques and cerebral amyloid angiopathy (CAA).14 Aggregation of Aβ has been suggested as an early event in the pathophysiology of AD, followed by the accumulation of hyperphosphorylated tau, and cognitive dysfunction. In this framework, intervention strategies have focused on anti-Aβ immunotherapy to halt a detrimental cascade of events. Long-term follow-up studies of the first active immunization trial (AN1792, Elan Pharmaceuticals Inc.) demonstrated that Aβ can be effectively removed from the brain.17,25 Subsequent passive immunotherapy trials similarly demonstrated Aβ clearance, culminating most recently in the US Food and Drug Administration’s (FDA) approval of aducanumab for the treatment of AD. One of the major obstacles in the development of successful passive anti-Aβ immunotherapies has been the occurrence of adverse events including Amyloid-Related Imaging Abnormalities (ARIA) on brain magnetic resonance imaging (MRI). ARIA can be observed in the form of signal hyperintensities on fluid-attenuated inversion recovery (FLAIR) thought to represent acute/subacute vasogenic edema and/or sulcal effusion termed ARIA-E, and signal hypointensities on T2\*-weighted gradient echo (GRE) MRI thought to represent hemosiderin deposits (e.g. microbleeds and cortical superficial siderosis) termed ARIA-H.1,4,35 When ARIA presents with symptoms, they can be managed with steroids and discontinuation of the anti-Aβ immunotherapy. 2 The first active immunization trial against Aβ was halted because of the development of meningoencephalitis in 6% of participants, which shared similarities with ARIA although the term had not been introduced yet at the time.23,26 Subsequent passive immunotherapy trials have reported ARIA in up to 47% of participants receiving the highest antibody doses.3,34 Most recent data from the phase 3 aducanumab trials indicated that ARIA-E was observed in 35% and ARIA-H in 19% (microbleeds) and 15% (cortical superficial siderosis) of patients treated with the highest dose (10 mg/kg). 32

The neuropathological associations and pathophysiological mechanisms of ARIA are currently unknown, although the presence of CAA has been suggested as a major contributing factor.6,35 Approximately 50% of patients with AD have moderate-to-severe CAA on post-mortem examination of the brain.18 The pathophysiology of CAA is postulated to involve a feed-forward cycle of impaired perivascular Aβ drainage, subsequent accumulation of Aβ in the walls of cortical arterioles and leptomeningeal arteries, smooth muscle cell degeneration, impaired vascular compliance, and further Aβ accumulation. Eventually this results in vessel wall breakdown, extravasation of plasma proteins into the brain, and hemorrhages.14 Brain hemorrhages in the form of lobar microbleeds, cortical superficial siderosis, and symptomatic lobar intracerebral hemorrhage are the hallmark neuroimaging manifestations of CAA and form the basis of the diagnostic criteria for CAA during life.13,19 A subset of patients with CAA presents with spontaneous ARIA-like imaging abnormalities and clinical symptoms in the form of vasogenic edema and hemorrhages, termed CAA-related inflammation. Analysis from Pittsburgh compound B (PiB)-PET imaging studies and cerebrospinal fluid (CSF) samples suggest that CAA-related inflammation may be the result of a spontaneous anti-Aβ immune response and immune-mediated Aβ removal from the brain. 2,9, 30 It remains unknown whether similar mechanisms play a role in the formation of ARIA in Aβ immunotherapy trials in AD patients. 27,36 So far, neuropathological investigations of ARIA have been limited due to the scarcity of appropriate autopsy cases. To address this knowledge gap, we performed ex vivo MRI in formalin-fixed brain tissue samples of cases that underwent active immunization with AN1792 against Aβ to screen for possible ARIA-H and to perform a detailed neuropathological investigation of the underlying tissue and vascular abnormalities. Our investigation was limited to hemorrhagic lesions as the transient nature of ARIA-E precludes the assessment of these lesions ex vivo.

**Materials and Methods**

*Human brain tissue*

Twelve cases with well-preserved formalin-fixed brain tissue from the long-term follow-up study of patients who enrolled in the first clinical trial of active Aβ immunization for AD (AN1792, Elan Pharmaceuticals Inc.) and provided consent for brain donation were included (iAD cases).25 Ethical approval was obtained though the Southampton and South West Hampshire Local Research Ethics Committees (REC reference 075/03/w). Brain tissue from eleven matched (for age, sex, fixation duration, and Braak stage) non-immunized AD cases were included as ‘controls’ (cAD cases) from the South West Dementia Brain Bank (SWDBB) (REC reference 18/SW/0029). One iAD case (case #1) had documented ARIA during life23 and as such was considered a positive control case. Two out of twelve iAD cases received placebo, of which 1 (case #14) proved not to have AD on neuropathological examination. As such, the placebo cases were excluded, and we considered the cAD cases to be the negative controls in this study.

Six additional non-AD control cases were included to control for long-term formalin fixation (Supplementary Material).

From each case, one intact formalin-fixed coronal brain slice from the occipital lobe from a single cerebral hemisphere was selected for ex vivo MRI scanning. The occipital lobe was selected as CAA tends to be more severe in the posterior parts of the brain.

For comparison, formalin-fixed brain tissue of a case from the Massachusetts General Hospital stroke research center with a clinical diagnosis of probable CAA and evidence of disseminated cortical superficial siderosis on in vivoMRI was added to the study.11 From this case, an intact formalin-fixed coronal brain slice from the occipital and frontal lobe from a single cerebral hemisphere was selected for ex vivoMRI scanning.

Detailed case characteristics are presented in Table 1 and Supplemental Table 1.

*Ex vivo MRI*

Three-to-four slices were simultaneously scanned for each MRI scan session. Slices were submerged in 10% formalin at room temperature in a glass container that fit in the head coil of the MRI scanner. Care was taken to avoid air bubbles by gently shaking the tissue. Scans were acquired overnight on a whole-body 7 T MRI scanner (Siemens Healthineers, MAGNETOM, Erlangen, Germany) with a custom-built 32-channel head coil. The scan protocol included a T2\*-weighted GRE sequence (two averages each with three different flip angles were run with the following parameters: 10°, 20°, 30°, echo time 8.67 ms, repetition time 20 ms, voxel size 200 x 200 x 200 μm3, scan duration ~1 hour per run) and a T2-weighted turbo spin echo (TSE) sequence (four averages were run with the following parameters: echo time 63 ms, repetition time 1000 ms, voxel size 300 x 300 x 300 μm3, scan duration ~1 hour per run).

*Ex vivo MRI rating*

Since ARIA-H has not been described on ex vivoMRI before, two raters (AAS, a trained rater with 2 years of experience; and SJvV, an expert rater with >8 years of experience) screened the acquired MR images first for presence of hemorrhagic lesions. Hypointense signal abnormalities suggestive of cortical superficial siderosis11,20 were noted on the GRE scans in the form of curvilinear cortical hypointensities in both the positive control iAD case (case #1) and several other iAD cases (but not the cAD cases). In addition, we noted occasional rarefaction of the juxtacortical white matter in the form of confluent hypointense abnormalities in iAD cases. No notable differences between iAD and cAD cases were observed in any of the other neuroimaging features on the TSE scans, such as ischemic lesions, white matter hyperintensities, or enlarged perivascular spaces. After this initial screening, the GRE MRI scans were de-identified and re-assessed by two raters (MGK and SJvV, both expert raters with 5-10 years of experience) blinded to treatment status and clinical information. The inter-rater agreement for the assessment of focal or disseminated cortical superficial siderosis was moderate (κ = 0.515), and for widespread (affecting >50 % of the tissue) white matter rarefaction was perfect (κ = 1.000). Discrepancies were resolved in a consensus meeting, after which a final rating was established.

*Histopathology*

In the iAD cases, areas with and without hemorrhagic lesions were sampled guided by ex vivo MRI and cut to fit a standard tissue cassette (measuring ~30 x 25 x 4 mm). In the cAD and non-AD cases, at least one area was sampled at the level of the calcarine cortex, and additional areas if abnormalities were observed on MRI. Collectively, from the iAD cases, a total of 10 samples were taken from areas with hemorrhagic lesions suggestive of ARIA-H (in the 5 cases with siderosis on MRI) and a total of 12 samples were taken from random areas without hemorrhagic lesions (in 5 cases without and 2 cases with siderosis on MRI). From the cAD cases, a total of 16 samples were taken. From the non-AD cases, a total of 7 samples were taken. Samples were processed and embedded in paraffin and cut in 6 μm-thick serial sections on a microtome.

Adjacent sections were stained with Hematoxylin and Eosin (H&E), Luxol fast blue H&E (LH&E) (for myelin), Perls’ Prussian blue (for iron), and Von Kossa (for calcium) using standard histology protocols. Immunohistochemistry was performed against pan-Aβ (clone 6F/3D, Dako, 1:200, Cat# M0872), hyperphosphorylated tau (AT8, Invitrogen, 1:400, Cat# MN1020), glial fibrillary acidic protein (GFAP, Sigma, 1:1000, Cat# G9269), phagocytic microglia (CD68, Dako, 1:500, Cat# M0814), and fibrin(ogen) (Dako, 1:500, Cat# A0080). The standardized immunohistochemistry protocol included deparaffinization and rehydration of the tissue through xylene and graded ethanol series, blocking of endogenous peroxidase with 3% H2O2 (20 min), treatment with formic acid (only for Aβ, 5 min), antigen retrieval in heated citrate buffer (only for GFAP, fibrin(ogen), and AT8, 20 min), blocking with normal horse or goat serum (1 hour), overnight incubation with the primary antibody at 4°C, incubation with a biotinylated mouse or rabbit secondary antibody (Vectastain ABC kit, Vector laboratories, 1 hour), followed by incubation with a mixture of avidin (A) and biotinylated HRP (B) (Vectastain ABC kit, Vector laboratories, 30 min), and development with 3,3'-Diaminobenzidine (DAB, Vector laboratories). Sections were counter stained with Hematoxylin (10 sec), dehydrated through graded ethanol series, and cover slipped with Fisher Chemical Permount mounting medium. In between steps sections were washed with tris-buffered saline.

*Histopathological image analysis*

All stained sections were scanned on a NanoZoomer whole slide scanner (Hamamatsu Photonics K.K., Japan) using a 20x objective, and the obtained digital images were assessed using the NDP.view2 viewing software (version 2.7.25).

Sections were de-identified and assessed by two independent raters (AAS and SJvV) blinded to MRI findings, treatment status, and clinical information, for the following: 1) number of microinfarcts on H&E and GFAP41, 2) number of microbleeds on H&E and Perls’41, 3) degree of concentric splitting of the wall of leptomeningeal blood vessels on H&E and Aβ-stained sections as absent, mild, moderate, severe (0-3)21, and 4) tau severity on AT8-stained sections as absent, mild, moderate, severe (0-3). Final ratings were established in a consensus meeting.

In addition, we obtained artificial intelligence (AI)-assisted quantitative measurements using the online platform Aiforia®. The methodology is described in detail elsewhere.29 Briefly, digital images were uploaded to the platform, after which several convolutional neural networks were trained on manual annotations (drawn by AAS) of histopathological features of interest on a representative subset of sections. Once fully trained, the AI-models were applied to all sections (one section per stain per area). We obtained the following quantitative measurements: 1) percentage cortical tissue area occupied by Aβ plaques, 2) percentage cortical tissue area occupied by CAA, 3) percentage leptomeningeal area occupied by CAA, 4) density of iron positive deposits within the cortex, 5) density of calcium positive cells within the cortex, 6) cell density of reactive (GFAP-positive) astrocytes within the cortex, 7) cell density of activated/phagocytic (CD68-positive) microglia in the cortex, and 8) percentage cortical tissue area occupied by fibrin-positive vessels.

*Statistics*

To assess whether hemorrhagic lesions resulting from immunotherapy could be detected on ex vivo MRI, the presence or absence of ex vivoMRI abnormalities was compared between iAD and cAD cases with χ2 tests for proportions. Clinical and general neuropathological observations were compared between iAD cases with and without presence of hemorrhagic lesions on ex vivo MRI with Mann-Whitney U tests for non-parametric data. Histopathological and vascular alterations between samples from cAD and iAD cases and samples with and without hemorrhagic lesions from iAD cases were compared with Mann-Whitney U tests and χ2 tests. Correlation analyses were performed with Spearman correlations. Cohen’s kappa was used to assess inter-rater reliability. All statistical analyses were performed with IBM SPSS version 22 and graphs were created with GraphPad Prism version 9.0.2. P-values of < 0.05 were considered statistically significant. Statistics were performed on the number of samples rather than number of cases.

*Data availability*

The original data that support the findings of this study are available from the corresponding author upon reasonable request.

**Results**

A total of 10 iAD cases (mean age at death 80.6 ± 8.1 years, 4 females) and 11 cAD cases (mean age at death 79.0 ± 5.4 years, 6 females) were included (Table 1). For the iAD cases, mean survival time from first immunization was 107 ± 57 months and 8/10 died as a result of advanced AD dementia.

*Ex vivo 7 T MRI findings*

On the ex vivo GRE 7 T MRI scan of iAD case #1, who had documented ARIA during life 12 months before death23, curvilinear hypointense abnormalities resembling cortical superficial siderosis were observed (Table 2, Figure 1). Similar abnormalities were observed in 4 other iAD cases, in the form of signal abnormalities resembling focal and disseminated cortical superficial siderosis. Such abnormalities were not observed in the cAD cases, except for one small area with subtle siderosis. Collectively, cortical superficial siderosis was observed in 5/10 iAD cases compared to 1/11 cAD cases (χ2 = 4.295, p = 0.038).

One microbleed was found in one of the cAD cases (this case had moderate CAA on routine neuropathological examination, Table 1), and none were observed in the iAD cases.

On the ex vivoTSE 7 T MRI scans, white matter hyperintensities and enlarged perivascular spaces were observed in 8/10 iAD cases and in 10/11 cAD cases (χ2 = 0.509, p = 0.476) (Supplemental Figure 1). Cortical microinfarcts were observed in 2/10 iAD cases and 3/11 cAD cases (χ2 = 0.153, p = 0.696).

*Histopathological correlates of hemorrhagic lesions*

Qualitative assessment revealed that the curvilinear hypointense signal abnormalities corresponded to iron-positive cellular and vascular deposits on Perls’ stained sections (Figure 2). The intracellular deposits also stained positive for calcium. Notably, brown hemosiderin deposits on H&E suggestive of more recent (i.e. shortly pre-mortem) hemorrhage were only observed in the iAD case with focal cortical superficial siderosis on ex vivo MRI (iAD case #17). Similar histopathological abnormalities were not present in the cAD cases, except for occasional extracellular calcium deposits in the cortex, which may be the result of long formalin fixation (see the Supplementary Material).

To help assess whether these findings are consistent with cortical superficial siderosis, we also analyzed a brain with pathologically confirmed CAA and evidence of disseminated cortical superficial siderosis during life (Supplemental Figure 2). Ex vivo MRI findings revealed widespread curvilinear hypointense abnormalities, extending more deeply into the sulci compared to iAD cases. Histopathological observations in areas with cortical superficial siderosis on ex vivo GRE 7 T MRI in this case confirmed previously reported findings of hemosiderin and iron deposits in the cortex in the context of severe CAA and concentric splitting of nearby leptomeningeal vessel walls.11 Adjacent sections stained positive for intracellular calcium deposits in the cortex, whereas no extracellular calcifications were observed in either the cortex or white matter.

*Clinical and general neuropathological correlations of hemorrhagic lesions*

Within the iAD group, the presence of cortical superficial siderosis on ex vivo MRI was not related to AN1792 dose, number of injections, antibody response, age at death, APOE ε4 status, or post-mortem interval (Mann-Whitney U tests, all p-values > 0.3) (Table 1).

*Quantification of histopathological alterations in iAD vs. cAD cases*

Using AI-assisted quantifications of Aβ, iron, and calcium on digitized histopathological images29, we found a greater density of intracellular iron and calcium deposits in the cortex in iAD cases (*n* = 22 samples) compared to cAD cases (*n* = 16 samples) (iron: U = 55, p < 0.001; calcium: U = 47, p < 0.001). Aβ plaque area (U = 97, p = 0.019) and tau severity (U = 72, p = 0.002, which was assessed semi-quantitatively) were both significantly lower in iAD compared to cAD samples, which is in line with previous reports in this cohort25 (Figure 3).

In terms of vascular alterations, percentage cortical CAA (U = 120, p = 0.101) and leptomeningeal CAA area (U = 130, p = 0.181) did not differ between iAD (*n* = 22 samples) and cAD cases (*n* = 16 samples). Moreover, severity of concentric vessel wall splitting (which was assessed semi-quantitatively) was comparable as well (U = 141, p = 0.421) (Figure 3).

*Quantification of histopathological alterations in areas with and without hemorrhagic lesions*

We next compared histopathological quantifications in areas with and without hemorrhagic lesions (i.e. cortical superficial siderosis) on ex vivo MRI in the iAD group. We found a greater density of iron deposits in areas with (*n* = 10 samples) compared to areas without hemorrhagic lesions (*n* = 12 samples) (U = 21, p = 0.009), but not intracellular calcium deposits (U = 37, p = 0.140). Aβ plaque area (U = 45, p = 0.346) and tau severity (U = 44, p = 0.314) did not differ between areas with and without hemorrhagic lesions (Figure 4).

Regarding vascular alterations, percentage cortical CAA area was comparable between areas with (*n* = 10 samples) and without hemorrhagic lesions (*n =* 12 samples) (U = 47, p = 0.418). However, we found greater leptomeningeal CAA area (U = 26, p = 0.025) as well as degree of concentric vessel wall splitting (U = 22, p = 0.020) in areas with compared to areas without hemorrhagic lesions (Figure 4). No relationship was found between hemorrhagic lesions and fibrin-positive vessels in the cortex (U = 45, p = 0.346).

*Microinfarcts and microhemorrhages*

A total of 21 microinfarcts were found in 6/22 samples of the iAD cases, compared to a total of 22 microinfarcts in 4/16 samples of the cAD cases (χ2 = 0.025, p = 0.875). Although there was no overall difference between the presence of microinfarcts in areas with and without hemorrhagic lesions (χ2 = 0.489, p = 0.484), 17/21 microinfarcts were observed in iAD case #1 in areas with hemorrhagic lesions on ex vivoMRI (Figure 4). While some degree of perivascular hemosiderin was occasionally present, frank microbleeds as observed in cases with severe CAA41 were absent on histopathology.

*Iron deposition is associated with lower Aβ plaque area*

Correlation analysis within the iAD group revealed that greater density of iron deposits in the cortex was associated with lower Aβ plaque area (*n* = 22 samples, Spearman’s ρ = -0.538, p = 0.010). Moreover, higher post-vaccination anti-AN1792 antibody titers were associated with lower Aβ plaque area (Spearman’s ρ = -0.444, p = 0.038) and tended to be associated with greater density of iron deposits in the cortex (Spearman’s ρ = 0.398, p = 0.067) (Figure 5). Collectively, these findings suggest that hemorrhagic lesions in the context of active immunization against Aβ may be related to successful Aβ removal from the parenchyma.

*Increased survival time is associated with increased reactive cells*

Notably, correlation analysis within the iAD group revealed that longer survival times were associated with greater densities of reactive astrocytes (Spearman’s ρ = 0.672, p = 0.001) and phagocytic microglia in the cortex (Spearman’s ρ = 0.788, p < 0.001) (Supplemental Figure 4).

**Discussion**

This study resulted in several main findings. We observed hemorrhagic lesions on ex vivo MRI in cases who received active immunization against Aβ during life. The ex vivo MRI and histopathological characteristics were consistent with cortical superficial siderosis, a known manifestation of severe CAA.11 Neuropathological examination confirmed locally severe vascular pathology of the leptomeningeal blood vessels, including greater vascular Aβ deposition and vessel wall splitting. The severity of cortical superficial siderosis was associated with lower Aβ plaque area and higher post-vaccination antibody titer levels. Finally, we observed greater presence of reactive glial cells in iAD cases with longer survival times.

Without inhemorrhagic lesions findingsare

The term ARIA refers to a spectrum of image abnormalities that can be observed throughout the natural course of AD and CAA and in the setting of amyloid-modifying therapeutic approaches.35 Two subtypes have been defined based on in vivo MR imaging characteristics; ARIA-E (cerebral edema and sulcal effusions on FLAIR MRI) and ARIA-H (cortical and superficial hemorrhages on T2\*-weighted MRI).35 Both subtypes were initially observed in active immunization trials and were defined as subacute meningoencephalitis26, and have now also been reported in multiple passive immunotherapy trials with rates of up to ~40% in the phase 1b and phase 3 aducanumab32,34 and phase 2 donanemab trials.22 ARIA is usually asymptomatic with symptoms reported in 1-26% of patients with ARIA-E.14, 32 Notably, the increased rate of ARIA-H in patients treated with passive immunotherapy as compared to placebo is more modest than differences in ARIA-E28, an effect largely driven by higher rates of pre-existing microbleeds in AD cases. In our study, we observed abnormalities suggestive of ARIA-H on ex vivo MRI in 5/10 iAD cases as compared to 1/11 cAD cases. Important risk factors for the development of symptomatic ARIA include immunotherapy dose, APOE ε4 allele status, and baseline number of cerebral microbleeds, with higher doses and/or faster up-titration of antibody and two copies of the APOE ε4 allele associated with increased incidence of ARIA.14 We did not find a relationship between hemorrhagic lesions and APOE ε4 status in the current study, which may be because all iAD cases had at least one allele as well as the modest sample size.

CAA has been proposed as a potential driver of ARIA formation, supported by shared risk factors between CAA and ARIA including APOE ε4 allele status and number of microbleeds as well as similarities between ARIA and CAA-related inflammation. Additionally, prior neuropathology findings have suggested increased CAA in iAD cases as well as increased concentric vessel wall splitting (i.e. lumen within a lumen appearance) detected in the frontal, temporal, and parietal lobes.5,31 We did not observe similar differences in our study between iAD and cAD cases. As we included brain slices from the occipital lobe, in which more severe CAA is typically observed, we suspect that any relative increase in CAA in the iAD cases may not have been detectable because of the higher baseline CAA severity in cAD cases in these occipital areas.

Our ‘positive control’ (iAD case #1) had symptomatic ARIA-E during life after receiving active Aβ immunization, confirmed by in vivo T2-weighted imaging.23 In vivo T2\*-weighted imaging was not available for this patient, which precluded us from verifying the presence of cortical superficial siderosis or other types of ARIA-H post-vaccination. An extensive neuropathological study of this case was previously published, demonstrating regions with likely Aβ plaque removal with relative persistence of CAA as well as T-lymphocyte meningoencephalitis.23 Of note, this was the only case in this cohort observed to have fulminant meningoencephalitis at autopsy.25 This case had the shortest interval between first immunization and death, possibly reflecting the severity of the adverse event. However, whereas other cases who received active immunization did not have any evidence of active meningoencephalitis at autopsy, neuropathological examination did provide evidence for Aβ plaque removal and increased CAA.17,25

Our findings extend this literature by adding the first direct histopathological investigation of hemorrhagic lesions in the context of Aβ immunotherapy. Without available in vivo MRI scans to verify whether these lesions indeed met criteria for ARIA-H during life, our findings may not be generalizable. The MRI characteristics were suggestive of cortical superficial siderosis as frequently observed in cases with severe CAA and one of the subtypes of ARIA in Aβ immunotherapy trials. Cortical superficial siderosis in CAA patients represents the chronic phase of convexity subarachnoid hemorrhage and increases the risk of future hemorrhagic stroke.10 Our histopathological findings are in line with previous observations in CAA autopsy cases with documented cortical superficial siderosis during life and are indicative of bleeding from the leptomeningeal blood vessels in the context of severe CAA.11 Notably, we previously reported increased leptomeningeal (but not cortical) CAA severity and concentric splitting of the walls (i.e. lumen within a lumen appearance) of leptomeningeal vessels in areas with siderosis on histopathology11, resembling our observations in iAD cases. Moreover, siderosis was associated with increased numbers of cortical microinfarcts, thought to be the result of secondary injury after leptomeningeal bleeding, which is in line with our findings in iAD case #1.

Although the cross-sectional nature of this investigation does not allow us to infer causes and consequences, potential mechanisms that could explain our findings in iAD cases are proposed as follows: perivascular drainage of Aβ from the cortex after immunization may have resulted in increased deposition of Aβ in leptomeningeal arteries5, resulting in vessel wall remodeling and fragmentation (in the form of vessel wall splitting)31 and subsequent leakage of blood products into the underlying cortex. An alternative interpretation of our findings is that the intraneuronal iron depositions observed in iAD cases are the result of released iron from local Aβ plaques after successful Aβ plaque removal. Previous studies have indeed demonstrated that Aβ plaques contain iron.12,16,37,40 In this scenario, our observations would not be related to bleeding and would likely be irrelevant to ARIA-H as observed during treatment trials. Although we cannot rule out this explanation, it does not account for the observed association with severe leptomeningeal CAA and concentric vessel wall splitting. Future studies, including longitudinal in vivo imaging studies in mouse models are needed to tease out the individual steps and exact sequence of events in ARIA formation.42

We found that longer survival times were associated with increased number of reactive glial cells, while previous studies reported an overall downregulation of neuroinflammatory protein expression following A removal.24,43 This observation is detected with the addition of cases with longer post-immunization survival times and thus could reflect that the response to ongoing neurodegenerative processes, such as tau pathology, is still progressing.6,25 Future studies are needed to determine the nature of these neuroinflammatory responses.

The observation of extracellular calcifications in the tissue with accompanying hypointensities on ex vivo GRE MRI in the iAD cases may reflect artefacts due to prolonged formalin fixation. A previous study reported similar-appearing granular neuropil changes on H&E in tissue that was fixed for more than six years.39 These alterations were also present in non-AD control cases, further suggesting these are irrelevant to ARIA-H. Moreover, similar abnormalities were not found in tissue from the same iAD cases embedded in paraffin after weeks of fixation. Importantly, Von Kossa staining of these samples embedded within weeks of fixation did demonstrate intracellular calcium deposits in the cortex in one of the most severely affected iAD cases (case #7). The adjacent iron stained section was also positive, but the signal was notably less strong than the iron stained sections in the tissue of the same case after years of fixation. One explanation for this apparent mismatch may be that formalin fixation augments endogenous intracellular iron and calcium depositions. However, reports in the literature that have examined the effect of formalin fixation on the concentration of minerals, including iron, either suggest no effect38, or significantly lower iron levels in formalin fixed compared to fresh tissue.33 Alternatively, the absence of in vivo or ex vivo MRI to guide sampling in previous studies may explain why these tissue alterations had not been observed before in this dataset and further underlines the importance of ex vivo MRI to bridge the gap between observations made during life and neuropathology. It is unclear why similar amounts of extracellular calcifications were not found in the cAD cases that were matched for years of fixation and stored under similar conditions as the iAD cases. We therefore cannot completely rule out the possibility that some of the white matter rarefaction in iAD cases reflects old edema in the setting of ARIA-E.

Besides the abovementioned caveats, this study has several additional limitations. First, because of the small number of cases that were available, we considered individual tissue blocks as independent samples. This can be considered a limitation given the unequal distribution of samples across cases. Second, only occipital brain slices were included in this study and it remains unclear whether similar alterations occur in other parts of the brain in which CAA is generally less severe. Third, because of the lack of established rating criteria for ARIA-H on ex vivo MRI, an initial unblinded screen was performed prior to blinded assessment by the same rater. Given the small sample size, this may have resulted in unintentional bias. Furthermore, rating ex vivo MRI scans remains challenging due to distortions (e.g. air trapped between stacked slices), which was reflected by a moderate inter-rater agreement. Of note, all neuropathological examinations were performed in areas where both raters agreed on the presence or absence of siderosis on ex vivo MRI locally. Fourth, since we did not have access to autopsy samples of patients who underwent passive immunotherapy during life, our findings may not be generalizable to anti-Aβ antibody treatments and ongoing studies that rely on passive immunotherapy.

*Conclusions*

This study demonstrates the added value of using ex vivo MRI to screen for ARIA-H. With the abovementioned significant limitations in mind, our findings suggest that Aβ immunotherapy may result in chronic cortical superficial siderosis in the context of severe leptomeningeal CAA and vascular remodeling. Whether secondary tissue injury caused by cortical superficial siderosis such as cortical microinfarcts and neuronal mineralization may contribute to further cognitive decline in AD patients with ARIA-H needs to be assessed in future studies. Collectively, the screening, clinical management, and ideally prevention of ARIA-H during Aβ immunotherapy trials are potentially relevant to limiting clinical deterioration, especially in AD patients with co-occurring CAA or APOE ε4 carriers who are at increased risk.14

**Acknowledgements**

Control tissue samples were obtained from the University Hospital Southampton NHS foundation Trust as part of BRAIN UK, which is funded by the Medical Research Council and Brain Tumour Research. Furthermore, we would like to thank the South West Dementia Brain Bank (SWDBB) for providing AD brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society and is supported by BRACE (Bristol Research into Alzheimer’s and Care of the Elderly) and the Medical Research Council. The immunized Alzheimer’s cases were provided by Profs. Boche and Nicoll from the University of Southampton, UK. Finally, we would like to thank Andre van der Kouwe and Corinne Auger (Boston, US) and Jeannette Norman from the Histochemistry Research Unit (Southampton, UK) for excellent technical assistance.

**Funding**

This work was funded by the National Institutes of Health (R00 AG059893 to SJvV) and the Netherlands Organization for Scientific Research (Veni 016.196.021 to SJvV). The collection of the immunized cases was supported by the Medical Research Council UK (G0501033 to DB) and Alzheimer’s Research UK (ART/PG2006/4, ART-EXT2010-1 to JARN and DB).

**Competing Interests**

SMG has served on safety monitoring committees or as consultant for AD immunotherapy trials conducted by Washington University, Biogen, and Roche. SJvV has served as consultant on CAA for Biogen. JARN has served as consultant relating to AD immunotherapy trials for Elan Pharmaceuticals, GlaxoSmithKline, Novartis, Roche, Janssen, Pfizer, and Biogen.

**Supplementary Material**

Supplementary Material is provided online.

**References**

1 Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, et al. (2020) The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis 7:146-151.

2 Antolini L, DiFrancesco JC, Zedde M, Basso G, Arighi A, Shima A, et al. (2021). Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study. Neurology97:e1809-e1822.

3 Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melançon D, et al. (2016) Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry 87:106-12.

4 Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, et al. (2013) MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 34:1958-65.

5 Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131:3299-310.

6 Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120:369-84.

7 Bulk M, Kenkhuis B, Van der Graaf LM, Goeman JJ, Natté R, Van der Weerd L (2018) Postmortem T2\*- Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer's Disease. J Alzheimers Dis 65:1125-1137.

8 Bulk M, Moursel LG, Van der Graaf LM, Van Veluw SJ, Greenberg SM, Van Duinen SG, et al. (2018) Cerebral Amyloid Angiopathy With Vascular Iron Accumulation and Calcification. Stroke 49:2081-2087.

9 Carmona-Iragui M, Fernández-Arcos A, Alcolea D, Piazza F, Morenas-Rodriguez E, Antón-Aguirre S, et al. (2016) Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. J Alzheimers Dis 50:1-7.

10 Charidimou A, Boulouis G, Greenberg SM, Viswanathan A (2019) Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis. Neurology 93:e2192-e2202.

11 Charidimou A, Perosa V, Frosch MP, Scherlek AA, Greenberg SM, van Veluw SJ (2020) Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy. Brain 143:3343-3351.

12 Everett J, Brooks J, Lermyte F, O'Connor PB, Sadler PJ, Dobson J, et al. (2020) Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42). Sci Rep 10:10332.

13 Greenberg SM, Charidimou A (2018) Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria. Stroke 49:491-497.

14 Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16:30-42.

15 Greenberg SM, Cordonnier C, Schneider JA, Smith EE, Van Buchem MA, Van Veluw SJ, et al. (2021) Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol 20:596-597.

16 Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG (1990) Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81:105-10.

17 Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-23.

18 Jäkel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM (2021) Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement [Epub ahead of print]. doi: 10.1002/alz.12366

19 Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56:537-9.

20 Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74:1346-50.

21 Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, et al. (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3:19-32.

22 Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. (2021) Donanemab in Early Alzheimer's Disease. N Engl J Med 384:1691-1704.

23 Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-52.

24 Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65:1040-8.

25 Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, et al. (2019) Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Brain 142:2113-2126.

26 Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54.

27 Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198-207.

28 Penninkilampi R, Brothers HM, Eslick GD (2017) Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Neuroimmune Pharmacol 12:194-203.

29 Perosa V, Scherlek AA, Kozberg MG, Smith L, Westerling-Bui T, Auger CA, et al. (2021) Deep learning assisted quantitative assessment of histopathological markers of Alzheimer’s disease and cerebral amyloid angiopathy. Acta Neuropath Commun 9:141.

30 Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. (2013) Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 73:449-58.

31 Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, et al. (2014) Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol 128:777-89.

32 Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. (2021) Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol [Epub ahead of print] doi: 10.1001/jamaneurol.2021.4161

33 Schrag M, Dickson A, Jiffry A, Kirsch D, Vinters HV, Kirsch W. (2010) The effect of formalin fixation on the levels of brain transition metals in archived samples. Biometals 23:1123-7.

34 Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537:50-6.

35 Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7:367-85.

36 Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol11:241-249.

37 Svobodová H, Kosnáč D, Balázsiová Z, Tanila H, Miettinen PO, Sierra A, et al. (2019) Elevated age-related cortical iron, ferritin and amyloid plaques in APP(swe)/PS1(deltaE9) transgenic mouse model of Alzheimer's disease. Physiol Res 68:S445-S451.

38 Van der Weerd L, Lefering A, Webb A, Egli R, Bossoni L (2020) Effects of Alzheimer's disease and formalin fixation on the different mineralised-iron forms in the human brain. Sci Rep 10:16440.


39 Van Duijn S, Nabuurs RJ, Van Rooden S, Maat-Schieman ML, Van Duinen SG, Van Buchem MA, et al. (2011) MRI artifacts in human brain tissue after prolonged formalin storage. Magn Reson Med 65:1750-8.

40 Van Duijn S, Bulk M, Van Duinen SG, Nabuurs RJA, Van Buchem MA, Van der Weerd L, et al. (2017) Cortical Iron Reflects Severity of Alzheimer's Disease. J Alzheimers Dis 60:1533-1545.

41 Van Veluw SJ, Scherlek AA, Freeze WM, Ter Telgte A, Van der Kouwe AJ, Bacskai BJ, et al. (2019) Different microvascular alterations underlie microbleeds and microinfarcts. Ann Neurol 86:279-292.

42 Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, et al. (2013) Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement 9:S105-15.

43 Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. (2013) Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain 136:2677-96.

****

**Figure 1.** Ex vivo gradient echo 7 T MRI reveals hemorrhagic lesions in iAD, but not cAD cases.

Top row shows examples of curvilinear cortical hypointensities (arrows) that were observed on ex vivo gradient echo (GRE) 7 T MRI scans of formalin-fixed coronal slices in five out of ten iAD cases, representative of cortical superficial siderosis. Similar abnormalities were not observed in cAD cases (bottom row), except for a small area of cortical hypointensity in one case (arrow). Note the appearance of confluent hypointense abnormalities in the white matter in case 102-6, which may reflect tissue rarefaction related to formalin fixation, and was observed in four out of ten iAD cases, but not in the cAD cases.

**Calendar

Description automatically generated**

**Figure 2.** Observed hemorrhagic lesions on ex vivo MRI correspond to iron and calcium deposits on histopathology.

An area with curvilinear cortical hypointensities (arrows) on ex vivo gradient echo (GRE) 7 T MRI in positive control iAD case #1 (A) revealed on histopathology tissue abnormalities in the cortex on H&E (B), which were confirmed as intracellular iron positive depositions on an adjacent Perls’ Prussian blue-stained section (C), and intracellular calcium depositions on an adjacent Von Kossa-stained section (D). In another iAD case with a more severe degree of cortical hypointensities (E, arrows), the corresponding histopathological sections revealed more extensive tissue abnormalities (F), in the form of intracellular iron depositions (G), and intracellular calcium depositions (H). In another iAD case with focal cortical hypointensity (I, arrow), the corresponding histopathological sections revealed hemosiderin deposits at the level of the leptomeningeal vessels (J), which stained positive for iron (K), and calcium (L). The inset in (L) shows extensive leptomeningeal CAA as well as concentric vessel wall splitting as observed on an adjacent section that underwent immunohistochemistry against Aβ. The bottom row shows a representative example of one of the cAD cases, without abnormalities on ex vivo GRE 7 T MRI (M), H&E (N), Perls (O), or Von Kossa-stained sections (P). Note the presence of extracellular calcium depositions in (D, H, L, P), which may be the result of prolonged formalin fixation of banked tissue.

Diagram, engineering drawing

Description automatically generated

**Figure 3.** Histopathological comparison between samples retrieved from iAD and cAD cases.

A greater density of iron deposits was observed in the cortex in iAD cases (*n* = 22 samples in 10 cases) compared to cAD cases (*n* = 16 samples in 11 cases) (A, U = 55, p < 0.001). Aβ plaque area was lower in the cortex in iAD compared to cAD cases (B, U = 97, p = 0.019). Tau severity was lower in the cortex in iAD compared to cAD cases (C, U = 72, p = 0.002). Percentage cortical CAA was comparable between iAD and cAD cases (D, U = 120, p = 0.101), as was leptomeningeal CAA area (E, U = 130, p = 0.181), and severity of concentric vessel wall splitting (F, U = 141, p = 0.421). Box plots represent median with interquartile range. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001.

**Diagram, schematic

Description automatically generated**

**Figure 4.** Histopathological comparison between areas with and without hemorrhagic lesions in iAD cases.

A greater density of iron deposits was observed in cortical areas of iAD cases with hemorrhagic lesions (i.e. cortical superficial siderosis) on ex vivo MRI (*n* = 10 samples) compared to cortical areas of iAD cases without hemorrhagic lesions on ex vivo MRI (*n* = 12 samples) (A, U = 21, p = 0.009). Aβ plaque area (B, U = 45, p = 0.346) and tau severity (C, U = 44, p = 0.314) did not differ between areas with and without hemorrhagic lesions. Percentage cortical CAA was comparable between areas with and without hemorrhagic lesions (D, U = 47, p = 0.418). We found greater leptomeningeal CAA area (E, U = 26, p = 0.025) as well as degree of concentric vessel wall splitting (F, U = 22, p = 0.020) in areas of iAD cases with compared to areas of iAD cases without hemorrhagic lesions. Note that in one sample no leptomeningeal vessels were present to assess (F). The vast majority of microinfarcts were observed in positive control iAD case #1 (G). The insets show three representative examples of cortical microinfarcts on H&E. The inset in (3) shows a CAA-positive cortical vessel associated with the microinfarct. Box plots represent median and interquartile range. \* p < 0.05, \*\* p < 0.01.

Chart, diagram

Description automatically generated

**Figure 5.** Cortical iron deposition is associated with lower Aβ plaque area in iAD cases.

Iron positive depositions were often found in areas with evidence of Aβ plaque removal as shown here in iAD case #7 (A). Within the iAD group (*n* = 22 samples), density of intracellular iron deposits in the cortex was negatively correlated with percentage Aβ plaque area in the cortex (B, Spearman’s ρ = -0.538, p = 0.010). Density of intracellular iron deposits in the cortex tended to be positively correlated with post-vaccination anti-AN1792 antibody titers (C, Spearman’s ρ = 0.398, p = 0.067). Percentage Aβ plaque area in the cortex was negatively associated with post-vaccination anti-AN1792 antibody titers (D, Spearman’s ρ = -0.444, p = 0.038). \* p < 0.05, \*\* p = 0.01.

**Table 1.** Case characteristics.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case ID** | **Sex**  **(M/F)** | **AN1792 dose**  **(μg)** | **Injections**  **(nr.)** | **Antibody response**  **(mean titer)** | **Survival time from first**  **immunization**  **(months)** | **Dementia duration**  **(years)** | **Age at death**  **(years)** | **Time of death**  **(year)** | **Cause of death**  **(as per formal death certificate)** | **Neuropathology findings** | | | **Post-mortem interval (hours)** | **Braak stages** | **Evidence of plaque removal\*** | **APOE ε4 allele (copy nr.)** |
| **ABC scores** | **CAA** | **Other** |
| *Immunized Alzheimer’s disease (iAD)* | | | | | | | | | | | | | | | | |
| 102-1 | F | 50 | 5 | 119 | 20 | 6 | 74 | 2002 | Pulmonary embolism, DVT, neurological disorder | A3B3C3 | Numerous cortical microvascular lesions related to severe CAA | Meningoencephalitis | 30 | V/VI | ++ | 1 |
| 102-6 | M | 50 | 8 | 1707 | 57 | 7 | 81 | 2005 | Old age, Alzheimer’s disease | A3B3C3 | Severe CAA |  | 6 | V/VI | ++ | 1 |
| 102-7 | M | 50 | 8 | 4374 | 60 | 6 | 82 | 2005 | Old age, Alzheimer’s disease, cerebral atrophy | A1B3C0 |  |  | 16 | V/VI | +++ | 1 |
| 102-8 | M | 50 | 8 | 6470 | 64 | 10 | 63 | 2005 | Ischemic heart disease, coronary artery atherosclerosis | A1B3C1 |  |  | 6 | V/VI | +++ | 1 |
| 102-11 | M | 50 | 8 | 142 | 94 | 12 | 88 | 2008 | Bronchopneumonia and mucinous cystadenoma of pancreas (stented), dementia | A3B3C2 | Severe CAA |  | 8 | V/VI | + | 1 |
| 102-16 | F | 225 | 6 | 142 | 111 | 15 | 89 | 2009 | Cerebrovascular accident, dementia | A3B3C0 | Extensive capillary CAA | Small acute infarct left basal ganglia | Unk | V/VI | +++ | 1 |
| 102-17 | F | 50 | Unk | 0 | 141 | 13 | 86 | 2012 | Bronchopneumonia, Alzheimer’s disease | A3B3C3 |  | Small old right parietal infarcts, microvascular lesions entorhinal cortex | 7 | V/VI | + | 2 |
| 102-20 | M | 225 | 3 | 430 | 166 | 17 | 82 | 2014 | Alzheimer’s disease | A3B3C2 | Extensive capillary CAA |  | 15 | V/VI | +++ | Unk |
| 102-21 | F | 50 | 8 | 3045 | 173 | 18 | 87 | 2014 | Lower respiratory tract infection, dementia | A3B3C1 | Extensive capillary CAA |  | 96 | V/VI | +++ | 1 |
| 102-22 | M | 225 | Unk | 1313 | 184 | 18 | 74 | 2015 | Alzheimer’s disease | A3B3C3 | Extensive capillary CAA |  | Unk | V/VI | + | 2 |
| 102-14 | M | Placebo | 8 | 0 | 96 | 9 | 64 | 2008 | Alzheimer’s disease | A3B1C0 |  | TDP43+ inclusions, hippocampal sclerosis | 10 | I/II | - | 2 |
| 102-15 | F | Placebo | Unk | 7 | 104 | 12 | 93 | 2009 | Heart failure, ischemic heart disease, diabetes mellitus, Alzheimer’s disease | A3B3C3 | Moderate CAA | Severe arteriolosclerosis / rarefaction of cerebral white matter, several cortical microinfarcts | 72 | V/VI | - | 1 |
| *Control Alzheimer’s disease (cAD)* | | | | | | | | | | | | | | | | |
| 601 | M | n/a | n/a | n/a | n/a | 10 | 68 | 2000 | Advanced Alzheimer’s disease | B3 |  |  | 61 | VI | n/a | 0 |
| 668 | F | n/a | n/a | n/a | n/a | 15 | 71 | 2001 | Bronchopneumonia | B3 |  |  | 24 | VI | n/a | 2 |
| 674 | M | n/a | n/a | n/a | n/a | 3 | 81 | 2001 | Unk | B3 |  |  | 24 | VI | n/a | Unk |
| 679 | F | n/a | n/a | n/a | n/a | 5 | 82 | 2001 | Dementia | B3 |  |  | 110 | IV | n/a | 1 |
| 683 | M | n/a | n/a | n/a | n/a | 5 | 83 | 2002 | Unk | B3C3 |  |  | 48 | V | n/a | 0 |
| 685 | M | n/a | n/a | n/a | n/a | 10 | 74 | 2001 | Perforated benign esophageal ulcer, bronchopneumonia | B3C2 |  |  | 48 | V | n/a | 0 |
| 703 | F | n/a | n/a | n/a | n/a | 9 | 83 | 2003 | Unk | A3B3C2 |  |  | 48 | V | n/a | 1 |
| 705 | F | n/a | n/a | n/a | n/a | 10 | 82 | 2003 | Unk | A3B3C3 |  |  | Unk | V | n/a | 1 |
| 745 | F | n/a | n/a | n/a | n/a | 15 | 84 | 2006 | Sigmoid volvulus, bronchopneumonia | A3B3C3 | Moderate CAA | Severe arteriolosclerosis | 21 | VI | n/a | 0 |
| 763 | F | n/a | n/a | n/a | n/a | 9 | 80 | 2007 | Bronchial pneumonia, fragility of old age, severe dementia | A3B3C3 |  |  | 51 | V | n/a | 2 |
| 765 | M | n/a | n/a | n/a | n/a | 3 | 80 | 2007 | Bronchopneumonia | A3B3C2 | Moderate CAA |  | 24 | IV | n/a | 1 |
| *Cerebral amyloid angiopathy (CAA)* | | | | | | | | | | | | | | | | |
| CAA15 | M | n/a | n/a | n/a | n/a | n/a | 67 | 2017 | Unk | A3B1C1 | Severe CAA | Lobar hemorrhage right frontal lobe, remote microvascular lesions | 24 | I | n/a | Unk |

\*Evidence of plaque removal was assessed according to previous methods detailed in Nicoll et al.25

**Table 2.** Ex vivo 7 T MRI findings.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Case ID** | **Curvilinear cortical hypointensities**  **on ex vivo GRE MRI** | **White matter rarefaction**  **on ex vivo GRE MRI** | **Cortical microbleeds**  **on ex vivo GRE MRI (nr.)** | **Cortical microinfarcts**  **on ex vivo TSE MRI (nr.)** | **White matter hyperintensities**  **on ex vivo TSE MRI** | **Perivascular spaces**  **on ex vivo TSE MRI** | **Possible ARIA-H** |
| *Immunized Alzheimer’s disease (iAD)* | | | | | | | |
| 102-1 | yes, disseminated | no | 0 | 0 | yes (including tissue loss) | yes | yes |
| 102-6 | yes, disseminated | yes | 0 | 1 | no | yes, focally severe | yes |
| 102-7 | yes, disseminated | no | 0 | 0 | yes | yes, focally severe | yes |
| 102-8 | no | yes | 0 | 0 | yes | yes | no |
| 102-11 | no | yes | 0 | 0 | no | yes | no |
| 102-16 | yes, disseminated | no | 0 | 0 | no | yes | yes |
| 102-17 | yes, focal | no | 0 | 0 | no | no | yes |
| 102-20 | no | no | 0 | 0 | yes, severe | no | no |
| 102-21 | no | no | 0 | 1 | no | yes | no |
| 102-22 | no | yes | 0 | 0 | no | no | no |
| 102-14 | no | yes | 0 | 2 | no | yes, focally severe | no |
| 102-15 | no | no | 0 | 0 | no | yes | no |
| *Control Alzheimer’s disease (cAD)* | | | | | | | |
| 601 | no | no | 0 | 0 | yes | yes, focally severe | no |
| 668 | no | no | 0 | 0 | yes | no | no |
| 674 | no | no | 0 | 2 | no | yes | no |
| 679 | no | no | 0 | 0 | yes | yes | no |
| 683 | no | no | 0 | 0 | yes | yes | no |
| 685 | no | no | 0 | 1 | no | no | no |
| 703 | no | no | 0 | 0 | yes | yes | no |
| 705 | no | no | 0 | 0 | yes | yes | no |
| 745 | no | no | 1 | 6 | yes (including small infarct) | yes | no |
| 763 | no | no | 0 | 0 | no | yes | no |
| 765 | yes, focal | no | 0 | 0 | yes | yes | yes |
| *Cerebral amyloid angiopathy (CAA)* | | | | | | | |
| CAA15 | yes, disseminated | no | 11\* | 8\* | yes | yes | yes |

\*7/11 microbleeds and 6/8 microinfarcts were found in the occipital slice